Atrium acquires Orthos Europe B.V., a Netherlands-based company


    This acquisition will allow Atrium to increase its market share within
    the Dutch health and nutrition market by serving a wider spectrum of
    Health Care Practitioners

    QUEBEC CITY, Sept. 22 /CNW Telbec/ - Atrium Innovations Inc. (TSX: ATB)
is pleased to announce the acquisition of Orthos Europe B.V. ("Orthos"). With
its Nootdorp headquarters located in The Netherlands, Orthos' subsidiary, AOV
Orthomoleculaire Voedingssupplementen B.V. ("AOV"), is renowned throughout
Holland for the development and marketing of high quality food supplements
through the Health Care Practitioner Channel. In 2007, AOV achieved annual
sales of 4.1 million euros (US$5.6 million). Atrium has acquired Orthos for a
total cash consideration of 7.6 million euros (approximately US$11 million).
    The acquisition of Orthos represents Atrium's second Netherlands-based
acquisition for 2008. Last February, Atrium announced the acquisition of MCO
Health B.V., a leading manufacturer and distributor of nutritional
supplements. "AOV's products will be a value-added complement next to MCO
Health's flagship brand: Orthica. The Orthica brand is specifically marketed
to general practitioners and dietary specialists, and sold through pharmacists
and other specialised outlets; while the AOV portfolio of products are
marketed and sold primarily through Complementary and Alternative Medicine
practitioners and other professionals. With these two key brands, AOV and
Orthica, Atrium has a solid platform from which to grow within the Benelux
region. Both companies clearly provide top quality products that meet Atrium's
rigorous science-based standards for health and nutritional products," said
Dr. Serge Yelle, Atrium's Executive Vice President, Operations.

    About Orthos

    For more than 20 years, Orthos and its subsidiary AOV have played an
instrumental role in the development of the Dutch food supplement market. AOV
is extremely well recognized for its association with the Foundation
"Stichting Orthomoleculaire Educatie", which plays a prominent role in the
education and training of Dutch orthomolecular healthcare practitioners. AOV's
food supplement portfolio provides its customers with a complete range of over
170 high valued products composed of vitamins, minerals, fatty acids, enzymes,
antioxidants, multi-vitamins/minerals, amino acids, phytotherapeutics and
other specific preparations.

    About Atrium

    Atrium Innovations Inc. is a recognized leading developer, manufacturer
and marketer of science-based and professionally endorsed products for the
health and nutrition industries. Atrium focuses primarily on growing segments
of the health and nutrition markets which are benefiting from the trends
towards healthy living and the ageing of the population. Atrium markets a
broad portfolio of finished products through its highly specialized sales and
marketing network in more than 35 countries, primarily in North America and
Europe. Atrium has over 575 employees and operates five manufacturing
facilities.

    Cautionary Note and Forward-Looking Statements

    This press release contains certain forward-looking statements with
respect to the Company. These forward-looking statements, by their nature,
necessarily involve risks and uncertainties that could cause actual results to
differ materially from those contemplated by these forward-looking statements.
The Company considers the assumptions on which these forward-looking
statements are based to be reasonable, but cautions the reader that these
assumptions regarding future events, many of which are beyond its control, may
ultimately prove to be incorrect since they are subject to risks and
uncertainties that affect the Company. For additional information with respect
to these and other factors, see the Company's quarterly and annual filings
with the Canadian securities commissions. The Company disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, other than as required
by law.



For further information: Investor Relations: Mario Paradis, Vice
President and Chief Financial Officer, (418) 652-1116,
mparadis@atrium-innov.com; Media Relations: Frédéric Tremblay, HKDP, (514)
395-0375, ext. 234, ftremblay@hkdp.qc.ca